Arden ratio at last follow-up examination (lower limit of normal = 180%).
In general, ocular findings were symmetrical between the two eyes. The VF, ERG and EOG of the better eye are presented.
the ones expected to benefit most from the treatment, were younger than 10 years of age. As the retinopathy of ABL often manifests at the end of the first decade or even later, it was not possible to determine the efficacy of vitamin treatment for a prolonged period. Presently, only one other study, which also included 8 patients, has addressed the question of the long-term efficacy of vitamin treatment started at an early age.17
The present report serves to extend our observations on 6 patients included in the original study1 
Patients and methods

Patients
We sequentially evaluated 10 ABL and 3 homozygous HBL patients. DiagnosiS of ABL and homozygous HBL was based on typical clinical findings (Table 1) 
Electroretinogram (ERG) and electro-oculogram (EOG)
ERG was performed as described in detail elsewhere.
IS
In short, full-field ERGs were recorded using corneal retinopathy. Note that the degree of retinopathy is more severe in this patient, who began treatment at the age of 5 years.
Results
Patient characteristics, electrophysiological and visual
field results are presented in Table 1 . Two to six years of follow-up of patients numbered 5-10 in Table 1 We classified our patients into two groups according to the age at which treatment was initiated. Group A included 8 ABL and 2 HBL patients in whom vitamin therapy was started before the age of 2 years. In this group, 4 of 6 patients older than 17 years and 1 patient aged 6 years had fundoscopic changes that can best be
Lower limit of normal described as an 'exaggerated tigroid fundus' (Fig. 1a) . (Fig. 1b) . None of the patients had the 'RP-like' pigmentary changes described previously in both treated and untreated ABL patients. Eight of the 10 patients in group A had mild to moderate reduction of the scotopic mixed cone-rod b wave at the end of follow-up (Fig. 2) . The scotopic rod ERGs were more affected than the cone ERGs ( Table 1) . Four of the 7 patients in this group for whom perimetry was available demonstrated mild constriction of the visual fields (40°-50° on the Goldmann V4e isopter).
In contrast to the ERG results, 9 of the 10 patients had a normal EOG, and at the end of follow-up all patients in group A were free of the neurological or systemic complications that are usually associated with untreated ABL and HBL.
Group B included 2 ABL patients and 1 HBL patient in whom vitamin supplementation was initiated at the ages of 11, 26 and 5 years respectively. One patient manifested RP-like fundus changes; the second patient showed small mid-peripheral chorioretinal scars, diffuse retinal pigment epithelium atrophy and mild narrowing of the arteries; while the third patient had 'salt and pepper' retinopathy in which the whitish component predominated (Fig. Ie) . All 3 patients had severe constriction of the visual fields and low EOG Arden ratios (l40-150%, Table 1 ). A markedly reduced ERG that was stable under vitamin treatment for 10 years was observed in one patient (no. 12), while ERGs deteriorated despite treatment in the 2 other patients of this group (nos. 11, 13) until they were non-recordable at the last available ERG examination (Fig. 2) . Two patients had ataxia and 1 also had peripheral neuropathy. However, under vitamin treatment these neurological complications did not seem to progress.
During follow-up, blood levels of beta-carotene were between 15 and 151 mg/100 ml in all patients (normal: 20-500 mg/IOO ml), and vitamin E levels were between 0.03 and 0.35 mg/100 ml in all patients (normal: 0.5-1 mg/100 ml). Adipose tissue biopsy performed in patients 3 and 7 revealed normal vitamin E levels. None of the patients in the present study had side-effects related to vitamin A toxicity, and this is to be expected considering the relatively low vitamin A blood levels. However, it should be mentioned that in our previous repore5 1 of the patients had pseudotumour cerebri that was attributed to vitamin A toxicity. Treatment was discontinued and subsequently this patient was lost for follow-up.
Discussion
ABL and homozygosity to HBL are considered to be rare instances in which appropriate treatment can prevent or delay progression of a retinal degeneration. The basis for combined vitamin A and E treatment in these patients stems from both clinical and laboratory data: since untreated ABL and homozygous HBL patients have extremely low vitamin A and E blood levels and as vitamin A plays a crucial role in phototransduction, it is within reason to expect that replacement therapy with vitamin A may be beneficial in these patients. Evidence also exists that vitamin E is important for normal retinal function. Deficiency of vitamin E can cause retinopathy in the dog, rat and monkey.zO-22 In humans, deficiency of vitamin E in several disease states was found to be associated with retinal degeneration and visual field constriction.z3 Furthermore, Robison et a1.22 demonstrated that combined deficiency of vitamin A and E in the rat can cause synergistic impairment of retinal function.
Clinical data on the efficacy of vitamin supplementation in ABL was initially collected in the early 1960s. At the time, ABL patients were treated by high oral or intramuscular doses of vitamin A alone. Variable short-term success in slowing progression of retinal disease, improving dark adaptation, and in regaining recordable ERG responses in patients that previously had extinct ERGs were reported. However, some ABL patient did not respond to vitamin A treatment, and in those who did, the protective effect of vitamin A on the retina was temporary. [24] [25] [26] Although ABL patients have been receiving combined vitamin A and E treatment since the early 1960s, only a small number of reports have addressed the question of intermediate and long-term benefits of this treatment. Muller and associates and Runge and associates17,27-29 described in detail the long-term follow-up of 7 ABL patients and 1 homozygous HBL patient who received combined vitamin A, E and K therapy, while maintaining a low-fat diet. In their most recent publication in 1986, 1 7 12-18 years of follow-up of 6 patients aged 13-26 years was reported. Four of these 6 patients had some degree of abnormal retinal pigmentation or pigment mottling, despite the fact that 2 of them began vitamin treatment prior to the age of 2 years. One of the patients also had constriction of the visual fields. However, in Runges' report, at the end of follow-up all patients had normal ERGs. In addition, the progression of both the retinal degeneration and the neurological deficts halted under vitamin A and E treatment in all patients. Therefore, the authors concluded that such treatment could prevent retinal and neurological manifestations of ABL. Another group of 10 ABL patients, on whom electrophysiological and clinical follow-up of up to 3 years was available, was reported in 1986 by Brin et a1.30 Six of 7 patients who underwent ERG testing had abnormal ERG responses. It is important to note that all patients in this report, except one, were older than 19 years at the time of first examination. One patient was 3 years old at the time of the first ERG examination and he too had subnormal responses. Over the 3 years of follow-up the authors did not see progressive retinal degeneration in patients with normal vitamin A levels on adequate supplementation of vitamin E. The authors concluded that replacement therapy with vitamin A and E can stabilise or improve neurological and ophthalmic lesions that are associated with ABL.
In 1982 our group reported on 8 ABL patients with a follow-up of 2-6 years.1S Seven patients who received combined vitamin A and E treatment had stable ERG amplitudes. In the 4 patients in whom treatment was initiated before 2 years of age, the fundi were normal and the ERGs stable throughout the follow-up period. However, these 4 patients were less than 5 years old at the end of follow-up. Three of the patients reported began treatment after the age of 8 years at a time when ERG amplitudes were already reduced. Under treatment, retinal degeneration did not progress, but the ERG did not return to normal values.
Data on the retinal degeneration that is associated with HBL, and on its treatment by fat-soluble vitamins, is very limited. One of the patients in Runge's report had homozygous HBL and responded well to vitamins A and E. Three other HBL patients, 2 of them heterozygous with mild retinal changes, and 1 homozygous with RP-like disease, were reported by Yee et aI. However, the efficacy of vitamin treatment was not evaluated in that report?
Our previous report with 2-6 years of follow-up showed preservation of retinal function under vitamin treatment.1S However, in that report, patients who began receiving therapy prior to 2 years of age were still young at the end of the study. In contrast, at the end of the present study, with longer follow-up, subnormal ERG amplitudes were observed in the majority of patients, even after receiving high oral doses of vitamin A and E from prior to 2 years of age. In addition, many had an abnormal fundus appearance and constriction of the visual fields. These abnormalities in older ABL and HBL patients were probably not witnessed by Bishara et aes due to the young patient age at that time. Our findings also differ from those described by Runge et al. 17 It is interesting that although 2 of their patients began vitamin supplementation therapy at the relatively late age of 7 years, ERGs were normal in all their treated patients. Yet, in that report, 1 patient did have constricted visual fields and in 2 patients pigmentary changes were noted despite initiation of vitamin therapy prior to 2 years of age. Since the treatment protocol and timing of treatment initiation are similar, the discrepancy between our study and that of Runge et al. is difficult to reconcile.
From our experience, and as might be expected, patients who begin receiving vitamin therapy at an older age have a markedly worse prognosis than those who start treatment earlier. Indeed, 2 of our 3 patients in group B who began treatment at the ages of 5, 11 and 26 years showed progression of retinal degeneration despite treatment. Although previous reports are in accordance with those findings,IS,30,31 others have reported normalisation of the ERG even when treatment was initiated in patients in their teens,l?
How can the occurrence of retinal changes under vitamin therapy be explained? It is conceivable that vitamins A and E are deficient in target tissues despite high-dose oral supplementation. Generally, a dose of 100 mg/kg per day of orally administered vitamin E is advocated,16 Despite these high doses, serum vitamin E levels in previous reports, as well as in our patients, rarely exceed one half of the normal values.1S,I? These low levels of vitamin E are expected since vitamin E in plasma has no specific carrier and is transferred mainly by the triglyceride-rich lipoproteins VLDL and LDL that are absent in ABL patients. Despite low serum levels, tissue levels of vitamin E may be adequate. Therefore, adipose tissue biopsies were performed in 2 of our patients. In both cases vitamin E levels were normaL Serum levels of vitamin A, unlike those of vitamin E, accurately reflect the adequacy of treatment. In most of our patients vitamin A levels were within the normal range throughout the study period, A few patients intermittently had mildly subnormal vitamin A levels, but no correlation was found between vitamin A or E levels and severity of fundus changes, visual field constriction or ERG amplitudes. However, since testing of levels reflects only isolated time points, it is still possible that our patients did experience transient vitamin A or vitamin E deficiencies between tests that were sufficiently low and prolonged to cause retinal changes.
Alternatively, the retinal abnormalities in our patients may be the result of a deficiency of factors, other than fat soluble vitamins, that are perhaps important for normal retinal function, Essential fatty acids may play a role in retinal dystrophies. Abnormalities in fatty acid metabolism were found in RP patients and may contribute to the retinal pathology in these patients. [32] [33] [34] In ABL patients, low levels of linoleic acid in plasma and in red blood cell membranes have been reported?S In addition, 2 ABL patients who received supplementation of polyunsaturated fatty acids were reported to have favourable neurological outcome?? Therefore, it is pOSSible that patients are lacking specific fatty acids or other nutrients that are essential for preservation of normal retinal function.
It should be noted that our case-series study design is not ideal for assessment of treatment efficacy due to the lack of a control group, among other reasons. There is ample evidence that without treatment a very severe retinopathy (and neuropathy) ensues in ABL and HBL patients.12-14 Hence, vitamin supplementation that since the early 1960s has been known to be effective, is offered once diagnosis is made. It is rare to find untreated patients (other than very young ones) and we did not follow any such cases. Under these conditions, the only applicable study design is a case-series with comparison with normal controls and reference to the historical evidence of severe impairment in patients prior to the vitamin-treatment era.
We conclude that although long-term treatment with vitamin A and E, especially when begun at an early age, can significantly attenuate ophthalmic manifestations associated with ABL and homozygous HBL, retinal changes still occur. Pigmentary changes, constriction of visual fields and decreased ERG amplitudes may progress at an older age and result in significant functional impairment. Hence, more studies are needed in order to define the cause of the mild retinal degeneration noted in ABL and homozygous HBL patients while under vitamin A and E treatment. Further follow-up is required to assess whether the trend observed towards worsening of retinal function is indeed progressive; if it is, additional treatment modalities should be considered.
